TRCT
APTO

Tower Research Capital (TRC)’s Aptose Biosciences, Inc. APTO Stock Holding History

Tower Research Capital (TRC)’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6
Closed -$526 – 6399
2023
Q3 		$526 Buy
6
+5
+500% +$589 ﹤0.01% 5542
2023
Q2 		$135 Buy
+1
New +$207 ﹤0.01% 5782
2022
Q4 		– Sell
-20
Closed -$5K – 6681
2022
Q3 		$5K Buy
20
+4
+25% +$1.38K ﹤0.01% 5202
2022
Q2 		$5K Buy
+16
New +$7.65K ﹤0.01% 5141
2022
Q1 		– Sell
-14
Closed -$9K – 6886
2021
Q4 		$9K Sell
14
-42
-75% -$39.5K ﹤0.01% 4752
2021
Q3 		$54K Buy
+56
New +$70K ﹤0.01% 2907
2020
Q4 		– Sell
-1
Closed -$3K – 5498
2020
Q3 		$3K Sell
1
-18
-95% -$44.9K ﹤0.01% 4541
2020
Q2 		$55K Buy
19
+7
+58% +$22.6K ﹤0.01% 2975
2020
Q1 		$32K Buy
+12
New +$35.8K ﹤0.01% 1499
2019
Q4 		– Sell
-2
Closed -$2K – 4617
2019
Q3 		$2K Hold
2
– – ﹤0.01% 3769
2019
Q2 		$2K Buy
+2
New +$1.84K ﹤0.01% 3348
2018
Q4 		– Sell
-5
Closed -$6K – 4523
2018
Q3 		$6K Buy
5
+3
+150% +$4.02K ﹤0.01% 3069
2018
Q2 		$3K Buy
+2
New +$3.19K ﹤0.01% 3270
2018
Q1 		– Hold
0
– – – 4013
2017
Q4 		– Sell
-4
Closed -$3.09K – 4181
2017
Q3 		$4K Sell
4
-2
-33% -$1.34K ﹤0.01% 3427
2017
Q2 		$4K Buy
+6
New +$2.89K ﹤0.01% 2144
2017
Q1 		– Sell
-2
Closed -$1.02K – 4138
2016
Q4 		$2K Buy
+2
New +$1.25K ﹤0.01% 3494
2016
Q3 		– Sell
-2
Closed -$2.08K – 4683
2016
Q2 		$3K Hold
2
– – ﹤0.01% 3766
2016
Q1 		$2K Sell
2
-2
-50% -$2.39K ﹤0.01% 3487
2015
Q4 		$4K Sell
4
-18
-82% -$31.8K ﹤0.01% 3288
2015
Q3 		$43K Sell
22
-4
-15% -$8.9K ﹤0.01% 1131
2015
Q2 		$59K Buy
26
+8
+44% +$20.9K 0.01% 1242
2015
Q1 		$44K Buy
18
+6
+50% +$14.5K 0.01% 1583
2014
Q4 		$31K Buy
+12
New +$36.1K ﹤0.01% 1317

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Tower Research Capital (TRC)'s APTO Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of Aptose Biosciences, Inc. (APTO) in Q4 2023, closing a stake of 6 shares — an estimated $526 sold.

Tower Research Capital (TRC) first reported a position in APTO in Q4 2014 and held it in 23 quarters. The position peaked at $59K in Q2 2015. 25 funds tracked by Wall St. Rank hold APTO as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining Aptose Biosciences, Inc. position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6 Aptose Biosciences, Inc. shares in Q4 2023, an estimated $526.
  • Tower Research Capital (TRC) first reported a position in Aptose Biosciences, Inc. in Q4 2014 and held it in 23 quarters.
  • Tower Research Capital (TRC)'s Aptose Biosciences, Inc. position peaked at $59K in Q2 2015.
  • 25 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.